Vendor, Rancho Dominguez, CA
Molecular Express, Inc.
UEI R1JMHFESEKD5, CAGE 337D8
3 awards and $4,999,218 obligated between June 25, 2024 and July 16, 2026, 67% under full and open competition, against 9.3 offers on average where reported. 2 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 3 |
Hear when Molecular Express, Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Molecular Express, Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $2,999,352
- Soonest
- August 31, 2027
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in biotechnology (except nanobiotechnology) to National Institutes of Health, by dollars.
| Fisher Bioservices Inc.Rockville, MD | $101,554,099 |
| PPD Development LPWilmington, NC | $65,307,629 |
| Seattle Children'S HospitalSeattle, WA | $61,525,979 |
| Alpha Genesis Inc.Yemassee, SC | $55,645,143 |
| Psychogenics Inc.Paramus, NJ | $36,035,836 |
| Rho Federal Systems Division Inc.Durham, NC | $35,268,211 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- Design and Engineering of VesiVax® HIV Immunogen Formulations”
National Institutes of Health, National Institutes of Health Niaid
Award noticeSmall businessNAICS 541715California75N93024C00018Awarded to Molecular Express, Inc. for $1,999,866
Posted Jan 14, 20252 publications
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93024C00017Definitive Contract, August 22, 2024, Full and Open Competition, 16 offers | National Institutes of Health NiaidNational Institutes of Health | Vesivax TLR7 FormulaNAICS 541714, PSC AN12 | $2,999,352 |
| 75N93024C00018Definitive Contract, June 25, 2024, Full and Open Competition After Exclusion of Sources, 2 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Design and Engineering of Vesivax Hiv Immunogen FormulationsNAICS 541715, PSC AN12 | $1,999,866 |
| 75N93023C00033Definitive Contract, April 10, 2025, Full and Open Competition, 10 offers | National Institutes of Health NiaidNational Institutes of Health | Eoi::implementing the Presidents Department of Government Efficiency Cost Efficiency Initiative (March 19, 2025)::EOI Full TerminationNAICS 541715, PSC AN12 | $0 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 5 across 3 awards